title: Repurposing Drugs for Cognition in Schizophrenia.
abstract: Currently approved treatments for schizophrenia only minimally affect the cognitive features of the illness that are the most closely related to disability. Hence, there is now considerable effort to repurpose drugs for schizophrenia, and to seek agents that can improve cognition by targeting receptor systems other than the dopaminergic system. The results of these studies have been mixed thus far; however, this continues to be a high-priority area of schizophrenia research and an important unmet need.
authors.affiliation: VISN22 Mental Illness Research, Education and Clinical Center, VA Greater Los Angeles Healthcare System, Los Angeles, California, USA.|Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, California, USA.
authors.forename: Y S
authors.initials: YS
authors.lastname: Yang
authors.affiliation: VISN22 Mental Illness Research, Education and Clinical Center, VA Greater Los Angeles Healthcare System, Los Angeles, California, USA.|Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, California, USA.
authors.forename: S R
authors.initials: SR
authors.lastname: Marder
authors.affiliation: VISN22 Mental Illness Research, Education and Clinical Center, VA Greater Los Angeles Healthcare System, Los Angeles, California, USA.|Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, California, USA.
authors.forename: M F
authors.initials: MF
authors.lastname: Green
mesh_terms: D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003071:Cognition / Q000187:drug effects; D003072:Cognition Disorders / Q000188:drug therapy* / Q000453:epidemiology; D058492:Drug Repositioning; D004359:Drug Therapy, Combination; D018683:Excitatory Amino Acid Agents / Q000494:pharmacology; D006801:Humans; D018722:Nicotinic Agonists / Q000494:pharmacology; D018091:Receptors, AMPA / Q000378:metabolism; D016194:Receptors, N-Methyl-D-Aspartate / Q000378:metabolism; D012559:Schizophrenia / Q000188:drug therapy* / Q000453:epidemiology
chemical_list: D000893:Anti-Inflammatory Agents; D014150:Antipsychotic Agents; D018683:Excitatory Amino Acid Agents; D018722:Nicotinic Agonists; D018091:Receptors, AMPA; D016194:Receptors, N-Methyl-D-Aspartate